Results 11 to 20 of about 665,601 (301)
Immunogenicity and humanization of single‐domain antibodies [PDF]
The FEBS Journal, 2021 Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy‐chain antibodies, have many desirable properties as components of biologic drugs. However, their sequences may increase the risk of immunogenicity and antidrug antibody (ADA) development in humans, and thus, sdAbs are routinely humanized during development ...
Rossotti, Martin A. +3 more
openaire +2 more sources
Single-domain antibodies make a difference [PDF]
Science, 2021 A double hit with one antibody construct may avoid viral ...
Xavier, Saelens, Bert, Schepens
openaire +2 more sources
AMB Express, 2022 Adenovirus belongs to the family of Adenoviridae. As a vaccine carrier, it has high safety and stimulates the body to produce cellular immunity and humoral immunity.
Yi Cheng +8 more
doaj +1 more source
Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect
Journal of Translational Medicine, 2020 Background Monoclonal antibodies (mAbs) have been used for cancer therapy. They are large and have some disadvantages limiting their use. Smaller antibody fragments are needed as their alternatives. A fully human single-domain antibody (sdAb) has a small
Tao Chen +3 more
doaj +1 more source
Application Progress of the Single Domain Antibody in Medicine. [PDF]
Int J Mol Sci, 2023 The camelid-derived single chain antibody (sdAb), also termed VHH or nanobody, is a unique, functional heavy (H)-chain antibody (HCAb). In contrast to conventional antibodies, sdAb is a unique antibody fragment consisting of a heavy-chain variable domain. It lacks light chains and a first constant domain (CH1).
Tang H, Gao Y, Han J.
europepmc +3 more sources
Therapeutic Phage Display-Derived Single-Domain Antibodies for Pandemic Preparedness
Antibodies, 2023 Driven by necessity, the COVID-19 pandemic caused by SARS-CoV-2 has accelerated the development and implementation of new vaccine platforms and other viral therapeutics. Among these is the therapeutic use of antibodies including single-domain antibodies,
Janet M. Daly +2 more
doaj +1 more source
A comparison of the binding sites of antibodies and single-domain antibodies
Frontiers in Immunology, 2023 Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity. Antibodies (Abs) and single-domain antibodies (sdAbs) differ in the structures of their binding sites: most significantly, single-domain antibodies lack a light chain and
Gemma L. Gordon +5 more
openaire +3 more sources
Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody
Frontiers in Medicine, 2021 A single domain antibody (clone CC3) previously found to neutralize a vaccine strain of the chikungunya virus (PRNT50 = 2. 5 ng/mL) was found to be broadly neutralizing.
Jinny L. Liu +9 more
doaj +1 more source
Single domain antibody: Development and application in biotechnology and biopharma. [PDF]
Immunol RevSummaryHeavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago,
Yu T +4 more
europepmc +4 more sources
Single Domain Antibody application in bacterial infection diagnosis and neutralization
Frontiers in Immunology, 2022 Increasing antibiotic resistance to bacterial infections causes a serious threat to human health. Efficient detection and treatment strategies are the keys to preventing and reducing bacterial infections. Due to the high affinity and antigen specificity,
Qian Qin +11 more
doaj +1 more source